When screening for carnitine uptake disorder (CUD), the New Zealand (NZ) newborn screening (NBS) service identified infants as screen-positive if they had initial and repeat free carnitine (C0) levels of less than 5.0 μmol/L. Since 2006, the NBS service has identified two infants with biochemical and genetic features consistent with neonatal CUD and nine mothers with features consistent with maternal CUD. A review of the literature suggests that these nine women reflect less than half the true prevalence and that CUD is relatively common. However, the NZ results (two infants) suggest a very low sensitivity and positive predictive value of NBS. While patients presenting with significant disease due to CUD are well described, the majority of adults with CUD are asymptomatic. Nonetheless, treatment with high-dose oral L-carnitine is recommended. Compliance with oral L-carnitine is likely to be poor long term. This may represent a specific risk as treatment could repress the usual compensatory mechanisms seen in CUD, such that a sudden discontinuation of treatment may be dangerous. L-carnitine is metabolized to trimethylamine-Noxide (TMAO) and treated patients have extremely high plasma TMAO levels. TMAO is an independent risk factor for atherosclerosis and, thus, caution should be exercised regarding long-term treatment with high-dose carnitine of asymptomatic patients who may have a biochemical profile without disease. Due to these concerns, the NZ Newborn Metabolic Screening Programme (NMSP) initiated a review via a series of advisory and governance committees and decided to discontinue screening for CUD.
Introduction
Carnitine uptake disorder (CUD, OMIM #212140), also known as primary carnitine deficiency or carnitine transporter defect, is caused by a defect in the plasma membrane OCTN2 protein transporter due to autosomal recessive mutations in the SLC22A5 gene (Nezu et al. 1999) . CUD results in excessive urinary carnitine loss, leading to very low plasma carnitine levels and secondary low tissue levels (Treem et al. 1988) .
Carnitine is required for the transport of long chain fatty acids into the mitochondria and very low carnitine levels can lead to a deficiency in fatty acid beta-oxidation. Patients with CUD may present from infancy onwards with symptoms related to hypoglycemia during a catabolic illness, a Reyes syndromelike event, and/or cardiomyopathy (Stanley et al. 1991; Wang et al. 2001; Lamhonwah et al. 2002; Melegh et al. 2004; Amat di San Filippo et al. 2006) . Treatment with high-dose oral Lcarnitine is thought to prevent the classical manifestations of the illness.
When expanded newborn screening (NBS) using tandem mass spectrometry (MS/MS) technology was introduced in New Zealand (NZ) in December 2006, around 25 different fatty acid oxidation disorders and organic acidaemias were added to the panel, as expert opinion at the time considered these suitable for screening and MS/MS made this feasible. Each individual disorder was not considered in detail, as there was little information available about many of the rarer conditions. CUD was screened for using a cutoff of free carnitine (C0) of less than 5 μmol/L on the day two Guthrie card blood spot. Positive results were communicated and a second card obtained. This second card was generally taken between 10 and 21 days of age. If the C0 remained below 5 μmol/L (1st-99th centile in NZ screening laboratory 11-82 μmol/L), then the family was seen and both the mother and the child had the levels of carnitine species measured in a blood spot and urine.
With this protocol, the service has identified nine mothers and two babies with genetic and/or biochemical features consistent with CUD between 2006 and 2016 (birth rate approximately 60,000 per year). The women identified through their screen-positive infants did not have any history of childhood hypoglycemia or any evidence of cardiomyopathy on echocardiogram. There was a history of mild fatigue in two of the women, although examination was normal. The remaining individuals were well and often active in sport. None had complications during pregnancy or delivery. They were counseled regarding CUD and offered oral carnitine supplements, but compliance with treatment has been poor, with only two mothers continuing with treatment. The two neonates diagnosed with CUD have remained asymptomatic on oral L-carnitine.
Methods
The NZ Newborn Metabolic Screening Programme (NMSP) is governed and administered by its parent body, the National Screening Unit (NSU), and centrally funded by the NZ Ministry of Health (NZMOH). The NSU is responsible for the national coordination and governance of the breast cancer, cervical cancer, colon cancer, antenatal HIV, NZMBS, and newborn hearing screening programs (https://www.nsu.govt.nz).
Scientists from the NZ NMSP and clinicians from the National Metabolic Service meet weekly to discuss NBS protocols and procedures. In 2014, this group noted reports that the majority of CUD patients are asymptomatic (Rasmussen et al. 2014) and that the UK National Screening Committee had recommended that NBS for CUD should not be commenced based on the poor sensitivity and specificity of the screening test, the lack of a known phenotype/genotype correlation, the presence of many asymptomatic cases, and the lack of information on the best treatment for the mothers diagnosed by NBS (https://legacyscreening.phe.org.uk/ fattyacidoxidation).
Due to local concerns regarding the high number of mothers being diagnosed, and the uncertainly regarding the best treatment for these women, a literature review was conducted and, based on this, it was decided that screening for CUD should be formally evaluated against the Wilson and Jungner (1968) based NZ screening criteria (https://www.nsu. govt.nz/system/files/resources/screening_to_improve_health. pdf), with a view to making an application to stop screening if the results of the review so indicated.
Results
The assessment of CUD against the screening criteria is as follows.
1) The condition is a suitable candidate for screening.
It has traditionally been thought that CUD is a very rare disease, whereby patients are at high risk of symptoms (Wang et al. 2001; Lamhonwah et al. 2002; Melegh et al. 2004; Amat di San Filippo et al. 2006) . However, there is a lack of large case series or any prospective reports. Recent studies from the Faroe Islands, where there is a very high incidence of CUD due to up to three founder effect mutations, suggest that the majority of people with CUD are asymptomatic, albeit with a significant minority expressing fatigue, with little evidence of cardiac disease or histories suggestive of metabolic decompensation (Rasmussen et al. 2014 ). CUD appears to be a rare cause of cardiomyopathy (Sabater-Molina et al. 2018) , although, interestingly, there are a number of reports of CUD causing familial cardiomyopathy within specific families (Melegh et al. 2004; Yamak et al. 2007; Lahrouchi et al. 2017; Mutlu-Albayrak et al. 2015) , suggesting a phenotype/genotype correlation or, perhaps, a contributory modifying gene.
As outlined below, there is likely to be at least a few hundred patients with CUD in NZ. However, there has been only one case of a symptomatic adult CUD, and this was prior to 2006. A very low incidence of symptomatic CUD prior to the introduction of NBS has also been noted in the literature (Hoffmann et al. 2004; Wilcken et al. 2009 ). It, thus, seems highly likely that, similar to what was found in the Faroe Islands, the majority of people with biochemistry consistent with CUD in NZ are asymptomatic. Accordingly, it may not be a suitable candidate disease for screening.
2) There is a suitable test.
NBS for CUD is possible by detecting very low levels of C0 in the neonatal blood spot (Wilcken et al. 2001 ). However, a newborn's plasma carnitine level is primarily dependent on maternal levels and asymptomatic mothers with CUD can have unaffected babies with screen-positive low levels (Schimmenti et al. 2007; Lee et al. 2010) . Likewise, babies with CUD, if sampled in the first few days of life, may not yet have developed sufficiently low levels of C0 to test positive (Christodoulou et al. 1996) . The older the baby is when screened, the greater the sensitivity and specificity of NBS for CUD . NBS has detected relatively few cases of CUD (Couce et al. 2011; Lindner et al. 2011; Waisbren et al. 2013 ; https://www.clirr4s.org/msCard.aspx), suggesting that it is either one of the rarer disorders of fatty acid oxidation or the current NBS is not a particularly sensitive test.
The NZ NMSP has diagnosed nine mothers with CUD after finding levels of C0 < 5.0 μmol/L in their babies' initial NBS at day 2 and with the second follow-up card (Table 1) . However, it is very unlikely that all the women with CUD who have had children screened have been identified. The Region 4 Genetics Collaborative website suggests that around 50% of the diagnosed maternal CUD cases had babies with NBS C0 levels greater than 5.0 μmol/L (https://www.clir-r4s.org/ProjTools/ DiseaseRangeComp.aspx) and, thus, the NZ NBS service would have missed these cases. The Region 4 site will also reflect an underestimation of the true condition incidence, as obviously not all cases of maternal CUD are identified by NBS. There were approximately 580,000 births in NZ during this 10-year period and with a national average birth rate of 2.0 per woman during the period 2006-2015 (http://www.stats.govt. nz/browse_for_stats/population/births/BirthsAndDeaths_ HOTPYeDec16.aspx). This gives an estimate of approximately 290,000 women who have had babies during this period. There have been nine maternal cases of CUD identified and, using the above very conservative 50% estimate, there are likely to be at least another nine cases who were not identified, giving an estimated minimum prevalence of at least 18 cases in 290,000 or approximately 1 in 16,000. NZ has a population of 4.5 million and, thus, there should be around 280 cases of CUD in the country.
Presuming this 1 in 16,000 incidence estimated above occurs in newborns, then the NZ NMSP should have diagnosed at least 36 cases of CUD during this 10-year period. The experience of only two babies being diagnosed reveals that current testing using C0 less than 5 μmol/L at days 2-3 of life is a poor test with very low sensitivity. The NZ NMSP has had 84 babies with a days 2-3 C0 less than 5 μmol/L, and only two were confirmed to have CUD. This gives a positive predictive value of less than 3%. This could be improved with screening at a later age (Steuerwald et al. 2017) , although setting up another universal screening service just for CUD in NZ is impractical.
With the NZ screening protocol of a second follow-up card taken at 10-21 days, it is likely that some, and perhaps most, babies of mothers with CUD will have increased their C0 levels above the cutoff of 5.0 μmol/L, and, thus, the families would not be contacted by the screening service and the mothers will remain unidentified. For example, from 2006 to 2016, 73 babies with birth weights greater than 1500 g were shown to have days 2-3 C0 levels less than 5.0 μmol/L but had follow-up levels greater than 5 μmol/L, and, thus, the families were not seen. It seems likely that some, and perhaps many, of these babies had mothers with CUD (Table 1 ).
In conclusion, using low C0 in the day 2 Guthrie card is a poor test for the diagnosis of CUD, as the sensitivity, specificity, and positive predictive value is poor.
3) There is an effective and accessible treatment or intervention for the condition identified through early detection.
Treatment with high-dose oral L-carnitine is generally recommended in CUD, and patients with cardiomyopathy secondary to CUD respond to this. However, despite treatment, patients can continue to have very low levels of free carnitine in muscle (Rasmussen et al. 2015) . There are no prospective studies regarding the outcome of carnitine supplementation in previous asymptomatic CUD patients, with recommendation to treat based on anecdotal evidence and expert opinion. In light of the paucity of evidence, it is important that treatment is without harm.
Despite very low plasma carnitine levels, the majority of adults with CUD seem to be healthy. Thus, people with CUD must compensate for their low levels. Studies in the CUD mouse model suggest that tissue levels of carnitine are resistant to the effect of low plasma carnitine levels (Knapp et al. 2008) , and there is a compensatory increase in the expression of other genes involved in fatty acid oxidation and mitochondrial metabolism (Suenaga et al. 2004 ). In the CUD animal model, the compensatory increased expression of the carnitine palmitoyltransferase 1 gene is repressed with oral carnitine (Uenaka et al. 1996) . The NZ treatment experience is that there are difficulties with compliance in our adult CUD patients. This reflects the poor compliance with medications also seen in asymptomatic patients with other, more studied, conditions, such as hypertension and hypercholesterolemia (Abegaz et al. 2017; Phan et al. 2014) . Plasma carnitine levels drop rapidly over 1-2 days when CUD patients discontinue Lcarnitine (Treem et al. 1988) . Thus, there is a concern that chronic administration of high-dose oral L-carnitine may downregulate the usual compensatory protective intracellular mechanisms in humans, and a period of subsequent poor compliance may render the patient particularly susceptible to CUD disease, most importantly cardiomyopathy and arrhythmia in the short term. Dietary L-carnitine is metabolized by intestinal microbiota to trimethylamine-N-oxide (TMAO). Chronic supplementation with high-dose L-carnitine, as seen in patients with inborn errors of carnitine metabolism, leads to a massive increase in plasma TMAO levels (Miller et al. 2016 ). Blood TMAO levels have recently been shown to be strongly associated with cardiovascular and kidney disease (Tang et al. 2013; Suzuki et al. 2016; Koeth et al. 2013) . A potential association with cancer has also been identified (Bae et al. 2014) . Whether TMAO itself causes atherosclerosis or cancer or is a biomarker for some other causative factor is not yet clear (Aron-Wisnewsky and Clément 2016; Tang and Hazen 2014). Nonetheless, it would appear prudent to show caution in the use of long-term high-dose oral Lcarnitine supplementation until the exact risks of such treatment become clearer.
Thus, while oral L-carnitine supplementation appears to be beneficial and, indeed, potentially life-saving in cases of symptomatic CUD, there are no large prospective studies in asymptomatic patients. Taking into account the likely risk of non-compliance, particularly in asymptomatic patients and the theoretical and animal model reasons why treatment could be potentially harmful, it can be argued that lifelong treatment in a mainly asymptomatic disease may not be advisable and prospective studies of L-carnitine use in conditions such as CUD should be encouraged.
4)
There is high quality evidence, ideally from randomized controlled trials, that a screening program is effective in reducing mortality or morbidity.
Randomized controlled trials are not applicable for most inborn errors of metabolism and, thus, there are no studies for CUD showing that treatment of asymptomatic CUD patients is beneficial. The Faroe Islands studies show that plasma carnitine levels can be significantly improved in a population of CUD patients, but long-term treatment outcome studies are not available (Rasmussen et al. 2014) . Since the majority of people with carnitine levels consistent with CUD are asymptomatic, it is unlikely that morbidity and mortality would be reduced by increased identification and treatment.
5) The potential benefit from the screening program should outweigh the potential physical and psychological harm (caused by the test, diagnostic procedures, and treatment).
CUD screening in NZ has resulted in a large number of false-positive tests, with 73 families with babies with low day 2 C0 levels having to be contacted and retested, only to be found to have levels above 5.0 μmol/L on retesting. This process of retesting may cause psychological harm in some families (Schmidt et al. 2012) .
In those with CUD who are diagnosed via screening, the potential benefit is likely to be small, given the low risk of symptomatic disease. In addition, there are the possible physical harms of treatment outlined above and the psychological harm of a disease label like CUD.
While NZ has a fully funded state-provided healthcare system, nearly half the population opts for additional private healthcare coverage. The diagnosis of CUD would, depending on the insurance policy, complicate this process.
6) The healthcare system will be capable of supporting all necessary elements of the screening pathway, including diagnosis, follow-up, and program evaluation.
NBS is well supported in NZ by the national clinical metabolic service and the NZMOH and NSU. Patients with disease are usually followed by the nurses, dieticians, and consultants from the National Metabolic Service. L-carnitine medication and clinic visits are fully funded by the state health system; however, the resources of the clinical metabolic service are limited and identifying people with benign biochemical abnormalities does not have high clinical utility.
7)
There is consideration of social and ethical issues.
The NZ NMSP has had, effectively, 100% coverage since 1969 and is well accepted and, overall, clearly beneficial. The key social and ethical issue of screening especially applicable to CUD is that screening should do more good than harm, and there appears to be considerable potential for screening for CUD to do more harm than good.
Another issue with CUD is that, at least in NZ, many more mothers than infants are being diagnosed and, yet, the screening service is not set up for the purpose of adult screening.
8)
There is consideration of cost-benefit issues.
The laboratory cost of adding an additional test to the conditions detected by MS/MS of amino acids and acylcarnitines is negligible. The major costs come in follow-up, including retesting, diagnosis, and treatment. As outlined above, these costs are likely to be significantly more than the benefits obtained.
The process of stopping screening for CUD
The purpose of NBS is to diagnose infants with treatable serious disorders which meet the NZ screening criteria. As outlined above, the NZ screening experience, along with relevant literature, suggests that CUD does not meet the criteria for a good screening disease.
Based on the discussion outlined above, it was proposed that screening for CUD in NZ should be discontinued. This proposal was presented to the NMSP Technical Group, a governmentappointed group of health professionals with expertise in various aspects of NBS (https://www.nsu.govt.nz/healthprofessionals/newborn-metabolic-screening-programme/ newborn-metabolic-screening-programme). Upon acceptance of this proposal, a recommendation was then forwarded by the NMSP Technical Group to the governance group of the NSU, the National Screening Advisory Committee (NSAC, https://www.nsu.govt.nz/about-us-national-screening-unit/nsuadvisory-groups/national-screening-advisory-committee), who then made their own recommendation to the Ministry of Health's Chief Medical Officer and the Director of National Services Purchasing. The proposal to discontinue CUD screening was accepted and, from 16th June 2017, NZ no longer screens for CUD. The pediatricians and associated child healthcare workers of NZ were alerted to this change via a national email list sever mechanism.
Children diagnosed with CUD remain in the care of the metabolic service. Families who had a previously positive screened CUD child were offered testing of subsequent newborns for CUD. Maternal CUD cases were offered treatment with oral L-carnitine during pregnancy and, again, testing of offspring for low free carnitine levels with treatment as indicated.
Conclusion
Carnitine uptake disorder (CUD) is a potentially serious condition and treatment of symptomatic disease with high-dose oral L-carnitine and an emergency plan for times of catabolic stress is beneficial. However, CUD may be a much more common condition than previously acknowledged. The prevalence in New Zealand (NZ) is estimated to be at least 1 in 16,000, with the vast majority of patients likely to be asymptomatic.
Newborn screening (NBS) for CUD is problematic due to the poor sensitivity and positive predictive value of days 2-3 free carnitine (C0) on dried blood spots. Despite the NZ Newborn Metabolic Screening Programme (MSP) expressing the purpose of diagnosing presymptomatic babies with disease, the experience with CUD is that much greater numbers of mothers are being diagnosed with CUD. These women have been generally asymptomatic and probably represent a minority of the adults with CUD. Thus, at least in the NZ situation, NBS is almost certainly diagnosing only a small minority of the babies with CUD.
Noncompliance with L-carnitine therapy in previously long-term-treated patients may represent a particular risk factor for symptomatic disease. In addition, treatment with highdose oral L-carnitine is potentially harmful due to the high levels of trimethylamine-N-oxide (TMAO) seen in treated patients. It is a possible proatherosclerotic compound.
The screening for CUD in NZ has thus resulted in the minority of adults with CUD being treated for a probably mainly asymptomatic disease with a potentially harmful treatment.
Through a process of careful consideration at a number of governance levels, it was decided that the potential risks and harms of CUD screening outweighed the benefits, and screening was discontinued.
Treatment of known patients with CUD should focus on the emergency plan during times of intercurrent illness (Dixon and Leonard 1992) , regular monitoring for cardiomyopathy, and the judicious use of oral L-carnitine, while expressing the importance of compliance and with possible monthly metronidazole to limit the accumulation of potentially harmful TMAO.
The addition of disorders to NBS panels has generally been done on the basis of expert opinion based on knowledge of patients diagnosed symptomatically. These patients have clinical, biochemical, and genetic profiles typical of the condition. NBS can identify infants with a biochemical (and sometimes genetic) profile consistent with those of known patients, but mostly without the clinical phenotype. Considering that most monogenic diseases present as a spectrum of severity, it is not surprising that history has shown that NBS generally identifies more Bcases^of disease than presented symptomatically prescreening.
As discussed, CUD seems to exemplify this model and, indeed, have many more people with biochemistry consistent with the condition than presented symptomatically. The case of CUD presents a strong argument for the introduction of screening to be preceded by pilot studies. Indeed, no jurisdiction which has considered the introduction of screening for amino acid breakdown and fatty acid oxidation disorders by condition has included CUD in their screening panel.
BExpanded screening^for amino acid breakdown and fatty acid oxidation disorders was introduced to NZ as a package of all the conditions known to be detectable (excluding SCAD, as this was thought to be more a biochemical abnormality than disease). The NZ program is unusual in that the utility of screening is reviewed regularly, condition by condition, leading to both modification of screening protocols and stopping screening for some disorders.
As CUD does not seem to be a suitable condition for screening, there is no agreed policy on who to treat and treatment seems not to be beneficial. Repeat tests, especially in mothers and in low birth weight babies, cause more harm than good. Following a defined and published process, CUD was removed from the NBS panel in 2017.
Compliance with ethical standards All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000.
